Hence, use of an ADAM9 inhibitor for PCa treatment might exert unpredictable toxicities, just like other MMP inhibitors which were reported to induce intolerable musculoskeletal pain and inflammation in cancer treatment clinical trials36. The gene discussed is ADAM9; the disease is posterior cortical atrophy.